rs113488022
|
|
T |
0.800 |
CausalMutation |
CLINVAR |
Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
|
26678033 |
2016 |
rs113488022
|
|
T |
0.800 |
CausalMutation |
CLINVAR |
A patient with V600E BRAF-mutant melanoma and another with platinum-refractory epithelial ovarian cancer exhibiting PTEN loss and PIK3CA amplification demonstrated partial response by RECIST and GCIG-CA125 criteria, respectively.
|
25370471 |
2015 |
rs121913227
|
|
TT |
0.800 |
CausalMutation |
CLINVAR |
Database of genomic biomarkers for cancer drugs and clinical targetability in solid tumors.
|
25656898 |
2015 |
rs113488022
|
|
T |
0.800 |
CausalMutation |
CLINVAR |
BRAF-V600 mutations have no prognostic impact in stage IV melanoma patients treated with monochemotherapy.
|
24586605 |
2014 |
rs113488022
|
|
T |
0.800 |
CausalMutation |
CLINVAR |
Prognostic value of BRAF mutations in localized cutaneous melanoma.
|
24388723 |
2014 |
rs113488022
|
|
T |
0.800 |
CausalMutation |
CLINVAR |
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.
|
24508103 |
2014 |
rs113488022
|
|
T |
0.800 |
CausalMutation |
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
rs113488022
|
|
T |
0.800 |
CausalMutation |
CLINVAR |
Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
|
24583796 |
2014 |
rs113488022
|
|
T |
0.800 |
CausalMutation |
CLINVAR |
Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.
|
24576830 |
2014 |
rs113488022
|
|
G |
0.800 |
GeneticVariation |
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
rs121913227
|
|
TT |
0.800 |
CausalMutation |
CLINVAR |
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.
|
24508103 |
2014 |
rs121913227
|
|
TT |
0.800 |
CausalMutation |
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
rs121913227
|
|
CT |
0.800 |
CausalMutation |
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
rs121913351
|
|
G |
0.800 |
GeneticVariation |
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
rs121913351
|
|
T |
0.800 |
GeneticVariation |
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
rs121913377
|
|
TT |
0.800 |
GeneticVariation |
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
rs121913377
|
|
AT |
0.800 |
CausalMutation |
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
rs121913377
|
|
TT |
0.800 |
GeneticVariation |
CLINVAR |
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.
|
24508103 |
2014 |
rs113488022
|
|
T |
0.800 |
CausalMutation |
CLINVAR |
Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma.
|
23918947 |
2013 |
rs113488022
|
|
T |
0.800 |
CausalMutation |
CLINVAR |
Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.
|
23614898 |
2013 |
rs113488022
|
|
T |
0.800 |
CausalMutation |
CLINVAR |
Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma.
|
22972589 |
2013 |
rs121913227
|
|
CT |
0.800 |
CausalMutation |
CLINVAR |
Effect of dabrafenib on melanoma cell lines harbouring the BRAF(V600D/R) mutations.
|
23317446 |
2013 |
rs121913227
|
|
TT |
0.800 |
CausalMutation |
CLINVAR |
Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma.
|
22972589 |
2013 |
rs121913227
|
|
CT |
0.800 |
CausalMutation |
CLINVAR |
We have treated 45 patients with V600 mutated melanoma including patients with V600R mutation between July 2011 and October 2012 with the selective BRAF inhibitor dabrafenib (n=43) or vemurafenib (n=2) via a compassionate access programme.
|
23237741 |
2013 |
rs121913227
|
|
TT |
0.800 |
CausalMutation |
CLINVAR |
Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma.
|
23918947 |
2013 |